Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis.
about
The Role of MicroRNAS in Ankylosing SpondylitisEpigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesAssociation Study of IL-12B Polymorphisms Susceptibility with Ankylosing Spondylitis in Mainland Han Population.Identification of TLR2 and TLR4‑induced microRNAs in human mesenchymal stem cells and their possible roles in regulating TLR signals.miR-573 is a negative regulator in the pathogenesis of rheumatoid arthritis.An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Epigenetics of osteoarticular diseases: recent developments.Epigenetic alterations underlying autoimmune diseases.New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications.Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production.Genomics and epigenomics in rheumatic diseases: what do they provide in terms of diagnosis and disease management?Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1α expression in peripheral blood mononuclear cellsThe role of aberrant expression of T cell miRNAs affected by TNF-α in the immunopathogenesis of rheumatoid arthritis.Overexpression of miR-31 in Peripheral Blood Mononuclear Cells (PBMC) from Patients with Ankylosing Spondylitis.Identification of potential target genes for ankylosing spondylitis treatment.Evaluation of DNMT1 gene expression profile and methylation of its promoter region in patients with ankylosing spondylitis.MicroRNA-124 involves in ankylosing spondylitis by targeting ANTXR2.Aberrant T cell expression of Ca2+ influx-regulated miRNAs in patients with systemic lupus erythematosus promotes lupus pathogenesis.
P2860
Q26750680-1A009B60-6BF7-474E-BF26-C322F23C77C3Q28079715-0409620C-87EB-4879-BEE4-38F7AE04B195Q35672059-38E4EA5F-34AB-4416-B00C-CC24EACCCE9FQ36931263-65764D82-5517-4F96-8B32-55431EEAC7AFQ37402448-9A5E6F45-65E8-4046-AC95-35175DEA77CDQ37471686-7713D297-EA09-4263-9F61-4798407E64BDQ37649641-3D61B8D2-0254-4F8A-AFEA-221094C42C00Q38392120-5C9536E0-2D98-4D15-9CD0-C555C09EB4CEQ38694852-CB4C48A4-AB5A-41D3-B41F-63C64C4F8CAFQ38840984-46B5321D-1E58-41F4-A1B0-1E0527E06956Q38996212-9F91C967-4C81-43D0-8439-48AB8F34C716Q39446770-02E77C1E-FF7D-4977-816C-1EF0ADC898ABQ39616530-01F2D347-1AC3-4294-88E0-8FC09A8AF306Q41784804-9631846F-ACBF-4F19-A8E3-8B9A971D42E8Q47115001-BF45A24F-3CFD-4723-8060-B0EFDD1D6CE3Q47142554-87E72AEB-6708-4C8D-B19B-3BF2A1A98C11Q49712215-96D57DFC-231D-47A5-98F6-22A41CEE21F4Q50219702-275391A2-F5D1-497D-A18E-9C58138F5306Q53023578-DF9BA84F-30AC-477E-964F-2F6DD163F2CFQ53024197-B8DC3D53-B906-41BD-AEF7-EA07540A4B42
P2860
Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@en
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@nl
type
label
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@en
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@nl
prefLabel
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@en
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@nl
P2093
P2860
P356
P1476
Aberrant expression of microRN ...... tes to the immunopathogenesis.
@en
P2093
P2860
P356
10.1111/CEI.12089
P577
2013-07-01T00:00:00Z